JP2019527729A5 - - Google Patents

Download PDF

Info

Publication number
JP2019527729A5
JP2019527729A5 JP2019522614A JP2019522614A JP2019527729A5 JP 2019527729 A5 JP2019527729 A5 JP 2019527729A5 JP 2019522614 A JP2019522614 A JP 2019522614A JP 2019522614 A JP2019522614 A JP 2019522614A JP 2019527729 A5 JP2019527729 A5 JP 2019527729A5
Authority
JP
Japan
Prior art keywords
formulation
polypropylene glycol
therapeutic
ppm
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019522614A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527729A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/041691 external-priority patent/WO2018013673A1/en
Publication of JP2019527729A publication Critical patent/JP2019527729A/ja
Publication of JP2019527729A5 publication Critical patent/JP2019527729A5/ja
Pending legal-status Critical Current

Links

JP2019522614A 2016-07-13 2017-07-12 治療用タンパク質製剤のための安定化賦形剤 Pending JP2019527729A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662361793P 2016-07-13 2016-07-13
US62/361,793 2016-07-13
PCT/US2017/041691 WO2018013673A1 (en) 2016-07-13 2017-07-12 Stabilizing excipients for therapeutic protein formulations

Publications (2)

Publication Number Publication Date
JP2019527729A JP2019527729A (ja) 2019-10-03
JP2019527729A5 true JP2019527729A5 (enExample) 2020-08-06

Family

ID=60941865

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019522614A Pending JP2019527729A (ja) 2016-07-13 2017-07-12 治療用タンパク質製剤のための安定化賦形剤

Country Status (6)

Country Link
US (4) US10279048B2 (enExample)
EP (1) EP3484520A4 (enExample)
JP (1) JP2019527729A (enExample)
KR (1) KR20190027878A (enExample)
CA (1) CA3030422C (enExample)
WO (1) WO2018013673A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
WO2019036619A1 (en) * 2017-08-18 2019-02-21 Reform Biologics, Llc STABILIZING EXCIPIENTS FOR FORMULATIONS OF THERAPEUTIC PROTEIN
JP7256816B2 (ja) * 2018-03-07 2023-04-12 コメラ ライフ サイエンシズ，インコーポレイテッド タンパク質製剤用の賦形剤化合物
US11318183B2 (en) 2018-03-20 2022-05-03 Mankind Pharma Ltd. Stable pharmaceutical composition of vasopressin
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
US20200093884A1 (en) 2018-09-20 2020-03-26 Mark C. Manning Stable intranasal formulations of carbetocin
EP3852724A4 (en) 2018-09-20 2022-07-06 Levo Therapeutics, Inc. CARBETOCIN DRUG PRODUCT AND PROCESS FOR ITS MANUFACTURE
GB201904741D0 (en) * 2019-04-04 2019-05-22 Glaxosmithkline Ip Dev Ltd Novel process
WO2020213682A1 (ja) * 2019-04-19 2020-10-22 富士フイルム和光純薬株式会社 細胞外小胞の保存安定化剤及び保存安定化方法
EP4178529A1 (en) * 2020-07-07 2023-05-17 F. Hoffmann-La Roche AG Alternative surfactants as stabilizers for therapeutic protein formulations
WO2023203257A1 (en) * 2022-04-22 2023-10-26 Janssen Sciences Ireland Unlimited Company Freeze dried compositions

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2510633C3 (de) * 1975-03-12 1978-07-13 Boehringer Mannheim Gmbh, 6800 Mannheim Diagnostisches Mittel zum Nachweis von Eiweiß in Körperflüssigkeiten und dafür geeignete Indikatorfarbstoffe
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
US6039977A (en) * 1997-12-09 2000-03-21 Alza Corporation Pharmaceutical hydrogel formulations, and associated drug delivery devices and methods
WO2002076432A2 (en) * 2001-03-26 2002-10-03 Novartis Ag Pharmaceutical composition comprising a poorly water-soluble active ingredient, a surfactant and a water-soluble polymer
US7041088B2 (en) 2002-10-11 2006-05-09 Ethicon, Inc. Medical devices having durable and lubricious polymeric coating
DE10325198B4 (de) 2003-06-04 2007-10-25 Clariant Produkte (Deutschland) Gmbh Verwendung von alkoxylierten vernetzten Polyglycerinen als biologisch abbaubare Emulsionsspalter
US8025915B2 (en) 2006-01-11 2011-09-27 Schott Ag Method of preparing a macromolecule deterrent surface on a pharmaceutical package
CN106443002A (zh) 2007-10-22 2017-02-22 贝克顿·迪金森公司 评价在含有机基聚硅氧烷的悬浮液中蛋白质聚集的方法
CN101795680A (zh) * 2007-11-16 2010-08-04 波苏蛋白试剂公司 稳定蛋白质的辅剂
KR20120089843A (ko) * 2009-07-31 2012-08-14 사노피-아벤티스 도이칠란트 게엠베하 인슐린 링커 접합체를 포함한 프로드럭
WO2011134979A2 (en) * 2010-04-27 2011-11-03 Scil Technology Gmbh Stable mia/cd-rap formulation
US8802603B2 (en) 2010-06-17 2014-08-12 Becton, Dickinson And Company Medical components having coated surfaces exhibiting low friction and low reactivity
KR101924653B1 (ko) 2010-06-24 2018-12-03 제넨테크, 인크. 단백질-함유 제제를 안정화시키기 위한 알킬글리코시드 함유 조성물 및 방법
US9145457B2 (en) * 2011-03-25 2015-09-29 Amgen Inc. Sclerostin antibody crystals and formulations thereof
WO2013180650A1 (en) 2012-05-31 2013-12-05 Agency For Science, Technology And Research Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives
JP2015526471A (ja) * 2012-08-21 2015-09-10 ジェネシス リサーチ インスティチュート アントラサイクリン誘発性心毒性を治療または予防するための組成物および方法
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
CN104870019A (zh) 2012-11-27 2015-08-26 阿特根公司 用于稳定蛋白质和Fc结构域融合的融合蛋白的组合物
EP2968189A4 (en) 2013-03-15 2016-11-16 Ansun Biopharma Inc METHOD FOR PRODUCING INJECTABLE PROTEIN MICROPARTICLE SUSPENSIONS
CA2908819A1 (en) * 2013-04-22 2014-10-30 Glycotope Gmbh Anti-cancer treatments with anti-egfr antibodies having a low fucosylation
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations

Similar Documents

Publication Publication Date Title
EP2525787B1 (en) Liquid formulations for long-acting g-csf conjugate
EP2914246B1 (en) Stabilizer for hyaluronidase and liquid formulation comprising hyaluronidase
JP2016530321A5 (ja) イオン性液体を含有する注射用液状タンパク質製剤およびその使用
KR20140091707A (ko) 크실리톨로 안정화된 에타너셉트 제형
JP7223712B2 (ja) 安定なペプチド組成物
KR20190027878A (ko) 치료 단백질 제제용 안정화 부형제
CN104159614A (zh) TNF-α抗体的药物制剂
US20160120946A1 (en) Compositions comprising gc-macrophage activating factor and uses thereof
JP2019525951A5 (enExample)
WO2012012388A3 (en) Therapeutic protein compositions having reduced immunogenicity and/or improved efficacy
JP2019532949A (ja) 耐熱保護剤、室温で保存可能な豚コレラ生ワクチンの製造方法及びその使用
MX2015005230A (es) Composicion farmaceutica estable de peginterferon alfa-2b.
CN112656939B (zh) 一种针对血管内皮生长因子的人源化抗体的药物组合物
EP4003290B1 (en) Stabilizing therapeutic proteins with piperazin- or morpholine-containing zwitterionic buffering substances
JPWO2000000221A1 (ja) 水溶性乾燥組成物
CN105412942A (zh) 聚乙二醇化的重组产朊假丝酵母尿酸氧化酶冻干注射剂
US11229702B1 (en) High concentration formulations of adalimumab
CN115518151A (zh) 一种人类免疫缺陷病毒中和抗体制剂及其用途
CN101376022A (zh) 含聚乙二醇降纤酶的药物组合物
WO1999045953A1 (fr) Compositions contenant un cofacteur ii de l'heparine et techniques de stabilisation
CN110799188A (zh) 基于托品酰胺的眼用制剂
HK1175721A (en) Liquid formulations for long-acting g-csf conjugate
JPH07242562A (ja) 顆粒球コロニー刺激因子含有直腸投与製剤